Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
PRINCIPLES: Current evidence indicates that chronic kidney disease (CKD) can be detected by simple laboratory tests. This study aimed to evaluate the cost-effectiveness of microalbuminuria screening and subsequent treatment in different populations. METHODS: Cost-effectiveness of microalbuminuria screening in a cohort of simulated subjects aged ≥50 years was assessed using a validated microsimulation model. Microalbuminuria screening was simulated for 1-, 2-, 5- or 10-year intervals and for 3 groups: diabetes (DM), hypertension but no diabetes (HTN), and no diabetes or hypertension. Positive microalbuminuria screening was followed by treatment with angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs). The model outcomes evaluate costs from a health care system perspective. RESULTS: Screening of risk groups is cost-effective at a 2-year interval for the DM group with an incremental cost-effectiveness ratio (ICER) of 54,000 CHF/ Quality-Adjusted-Life-Years (QALY) and at a 5-year interval for the HTN group with an ICER of 33,000 CHF/QALY. Screening of the remaining population is cost-effective at a 10-year interval with an ICER of 34,000 CHF/QALY. The ICER improves with longer screening intervals for all groups. A probabilistic sensitivity analysis (PSA) confirmed 2-year, 5-year and 10-year intervals as the most cost-effective for the DM group, the HTN group and the remaining population respectively. CONCLUSIONS: Microalbuminuria screening can be considered cost-effective starting at the age of 50 years at bi-annual intervals for subjects with diabetes, at 5-year intervals for subjects with hypertension and at 10-year intervals for the remaining population. Our results indicate that early detection and treatment of CKD might lead to optimised patient care, and offer guidance for future implementation of CKD screening programmes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population
Cowie, C. C., Rust, K. F., Byrd-Holt, D. D., Eberhardt, M. S., Flegal, K. M., Engelgau, M. M., Saydah, S. H., Williams, D. E., Geiss, L. S., & Gregg, E. W. (2006) · Diabetes Care · doi:10.2337/dc06-0062 · Cited by 1,210
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
Probabilistic Sensitivity Analysis Using Monte Carlo Simulation: A Practical Approach
Doubilet, P., Begg, C. B., Weinstein, M. C., Braun, P., & McNeil, B. J. (1985) · Medical Decision Making · doi:10.1177/0272989x8500500205 · Cited by 860
Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold
Grosse, S. D. (2008) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.8.2.165 · Cited by 637
A comparative evaluation of various methods for microalbuminuria screening
Sarafidis, P. A., Riehle, J., Bogojevic, Z., Basta, E., Chugh, A., & Bakris, G. L. (2008) · American Journal of Nephrology · doi:10.1159/000111825 · Cited by 41
Cited by
Ene-Iordache, B., Perico, N., Bikbov, B., Carminati, S., Remuzzi, A., Perna, A., Islam, N., Bravo, R. F., Aleckovic-Halilovic, M., Zou, H., et al. (2016) · The Lancet Global Health · doi:10.1016/s2214-109x(16)00071-1 · Cited by 627
Mitochondrial dysfunction in obesity
de Mello, A. H., Costa, A. B., Engel, J. D. G., & Rezin, G. T. (2018) · Life Sciences · doi:10.1016/j.lfs.2017.11.019 · Cited by 508
Chale-Dzul, J., Pérez-Cabeza de Vaca, R., Quintal-Novelo, C., Olivera-Castillo, L., & Moo-Puc, R. (2020) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2019.12.183 · Cited by 47
Metadata
- Authors
- Kessler, R., Keusch, G. W., Szucs, T. D., Wittenborn, J. S., Hoerger, T. J., Brügger, U., & Wieser, S.
- Venue
- Swiss Medical Weekly
- Publisher
- SMW Supporting Association
- Published
- 2012-01-29
- Volume
- 142
- Issue
- 0506
- Pages
- w13508
- ISSN
- 0036-7672 (ISSN-L)
- 1424-3997
- OpenAlex
- W2158017832
- Cited by
- 64
- References
- 5
- FWCI
- 16.67
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. https://app.cochat.ai/papers/10.4414/smw.2012.13508
- The paper
- Kessler, R., Keusch, G. W., Szucs, T. D., Wittenborn, J. S., Hoerger, T. J., Brügger, U., & Wieser, S. (2012). Health economic modelling of the cost-effectiveness of microalbuminuria screening in Switzerland. Swiss Medical Weekly. https://doi.org/10.4414/smw.2012.13508
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.